These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 18268197)

  • 21. Reduced 25-hydroxyvitamin D and risk of Alzheimer's disease and vascular dementia.
    Afzal S; Bojesen SE; Nordestgaard BG
    Alzheimers Dement; 2014 May; 10(3):296-302. PubMed ID: 23871764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline.
    Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K
    Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Dietary Habits in Midlife With Dementia Incidence Over a 20-Year Period.
    Glans I; Sonestedt E; Nägga K; Gustavsson AM; González-Padilla E; Borne Y; Stomrud E; Melander O; Nilsson PM; Palmqvist S; Hansson O
    Neurology; 2023 Jan; 100(1):e28-e37. PubMed ID: 36224029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics.
    Bos I; Vos S; Vandenberghe R; Scheltens P; Engelborghs S; Frisoni G; Molinuevo JL; Wallin A; Lleó A; Popp J; Martinez-Lage P; Baird A; Dobson R; Legido-Quigley C; Sleegers K; Van Broeckhoven C; Bertram L; Ten Kate M; Barkhof F; Zetterberg H; Lovestone S; Streffer J; Visser PJ
    Alzheimers Res Ther; 2018 Jul; 10(1):64. PubMed ID: 29980228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting.
    Roberts RO; Aakre JA; Kremers WK; Vassilaki M; Knopman DS; Mielke MM; Alhurani R; Geda YE; Machulda MM; Coloma P; Schauble B; Lowe VJ; Jack CR; Petersen RC
    JAMA Neurol; 2018 Aug; 75(8):970-979. PubMed ID: 29710225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical significance of plasma clusterin and Aβ in the longitudinal follow-up of patients with Alzheimer's disease.
    Hsu JL; Lee WJ; Liao YC; Wang SJ; Fuh JL
    Alzheimers Res Ther; 2017 Nov; 9(1):91. PubMed ID: 29169407
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.
    Lieb W; Beiser AS; Vasan RS; Tan ZS; Au R; Harris TB; Roubenoff R; Auerbach S; DeCarli C; Wolf PA; Seshadri S
    JAMA; 2009 Dec; 302(23):2565-72. PubMed ID: 20009056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
    Frankfort SV; Tulner LR; van Campen JP; Verbeek MM; Jansen RW; Beijnen JH
    Curr Clin Pharmacol; 2008 May; 3(2):123-31. PubMed ID: 18700307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors.
    Stocker H; Nabers A; Perna L; Möllers T; Rujescu D; Hartmann A; Holleczek B; Schöttker B; Gerwert K; Brenner H
    Alzheimers Dement; 2020 Feb; 16(2):283-291. PubMed ID: 31611055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma amyloid-beta forms in Alzheimer's disease and non-Alzheimer's disease patients.
    Le Bastard N; Leurs J; Blomme W; De Deyn PP; Engelborghs S
    J Alzheimers Dis; 2010; 21(1):291-301. PubMed ID: 20421698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral glucose loading modulates plasma β-amyloid level in alzheimer's disease patients: potential diagnostic method for Alzheimer's disease.
    Takeda S; Sato N; Uchio-Yamada K; Yu H; Moriguchi A; Rakugi H; Morishita R
    Dement Geriatr Cogn Disord; 2012; 34(1):25-30. PubMed ID: 22889768
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biomarkers for insulin resistance and inflammation and the risk for all-cause dementia and alzheimer disease: results from the Framingham Heart Study.
    van Himbergen TM; Beiser AS; Ai M; Seshadri S; Otokozawa S; Au R; Thongtang N; Wolf PA; Schaefer EJ
    Arch Neurol; 2012 May; 69(5):594-600. PubMed ID: 22213409
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.
    Andreasen N; Hesse C; Davidsson P; Minthon L; Wallin A; Winblad B; Vanderstichele H; Vanmechelen E; Blennow K
    Arch Neurol; 1999 Jun; 56(6):673-80. PubMed ID: 10369305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating ceramide ratios and risk of vascular brain aging and dementia.
    McGrath ER; Himali JJ; Xanthakis V; Duncan MS; Schaffer JE; Ory DS; Peterson LR; DeCarli C; Pase MP; Satizabal CL; Vasan RS; Beiser AS; Seshadri S
    Ann Clin Transl Neurol; 2020 Feb; 7(2):160-168. PubMed ID: 31950603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association Between Serum β-Alanine and Risk of Dementia.
    Hata J; Ohara T; Katakura Y; Shimizu K; Yamashita S; Yoshida D; Honda T; Hirakawa Y; Shibata M; Sakata S; Kitazono T; Kuhara S; Ninomiya T
    Am J Epidemiol; 2019 Sep; 188(9):1637-1645. PubMed ID: 31127276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
    Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging.
    Mielke MM; Hagen CE; Wennberg AMV; Airey DC; Savica R; Knopman DS; Machulda MM; Roberts RO; Jack CR; Petersen RC; Dage JL
    JAMA Neurol; 2017 Sep; 74(9):1073-1080. PubMed ID: 28692710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease.
    Takeda S; Sato N; Rakugi H; Morishita R
    Mol Biosyst; 2010 Oct; 6(10):1760-6. PubMed ID: 20567751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer's Disease.
    Chatterjee P; Elmi M; Goozee K; Shah T; Sohrabi HR; Dias CB; Pedrini S; Shen K; Asih PR; Dave P; Taddei K; Vanderstichele H; Zetterberg H; Blennow K; Martins RN
    J Alzheimers Dis; 2019; 71(3):775-783. PubMed ID: 31424403
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.